GRI Bio
$1.8800
54
-$0.44-18.97% Thursday 19:59
Statistics
Day High
2.16
Day Low
1.81
52W High
80.36
52W Low
1.81
Volume
634,200
Avg. Volume
-
Mkt Cap
2.72M
P/E Ratio
0.06
Dividend Yield
-
Dividend
-
Upcoming
Earnings
19AugExpected
Expected EPS
-1.195
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-23.91MNet Income
Analyst Ratings
32.00Average Price Target
The highest estimate is 32.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow GRI. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap191.7B
Gilead Sciences
GILD
Mkt Cap155.93B
Biogen
BIIB
Mkt Cap29.53B
Vertex Pharmaceuticals
VRTX
Mkt Cap112.92B
Regeneron Pharmaceuticals
REGN
Mkt Cap64.18B
Moderna
MRNA
Mkt Cap19.8B
Alnylam Pharmaceuticals
ALNY
Mkt Cap37.76B
Biomarin Pharmaceutical
BMRN
Mkt Cap10.81B
Novartis
NVS
Mkt Cap292.07B
Holdings
Regions
Sectors
About
GRI Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutic agents within the United States. Its primary focus lies in addressing inflammatory, fibrotic, and autoimmune disorders. The company's leading drug candidate is GRI-0621, an oral inhibitor targeting type 1 Natural Killer T cells, which is currently undergoing Phase IIa clinical trials. This investigational treatment is being evaluated for severe fibrotic lung conditions, including idiopathic pulmonary fibrosis. Beyond its flagship program, GRI Bio's pipeline also features GRI-0803, a novel oral agonist designed to activate type 2 Natural Killer T cells, currently in preclinical development for autoimmune diseases. Additionally, the company maintains a proprietary library exceeding 500 compounds and includes GRI-0124 and GRI-0729, both aimed at modulating inflammatory immune responses. Founded in 2009 and headquartered in La Jolla, California, GRI Bio, Inc. was previously known as Glycoregimmune, Inc.
Show more...
CEO
Dr. W. Marc Hertz Ph.D.
Employees
3
Country
United States
ISIN
US3622AW5029
Listings
0 Comments
Share your thoughts
FAQ
What is GRI Bio stock price today?▼
The current price of GRI is $1.88 USD — it has decreased by -18.97% in the past 24 hours. Watch GRI Bio stock price performance more closely on the chart.
What is GRI Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange GRI Bio stocks are traded under the ticker GRI.
Is GRI Bio stock price growing?▼
GRI stock has fallen by -16.44% compared to the previous week, the month change is a -15.7% fall, over the last year GRI Bio has showed a -95.2% decrease.
What is GRI Bio market cap?▼
Today GRI Bio has the market capitalization of 2.72M
When is the next GRI Bio earnings date?▼
GRI Bio is going to release the next earnings report on August 19, 2026.
What were GRI Bio earnings last quarter?▼
GRI earnings for the last quarter are -1.61 USD per share, whereas the estimation was -1.61 USD resulting in a -0.31% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is GRI Bio revenue for the last year?▼
GRI Bio revenue for the last year amounts to 0 USD.
What is GRI Bio net income for the last year?▼
GRI net income for the last year is -23.91M USD.
How many employees does GRI Bio have?▼
As of June 19, 2026, the company has 3 employees.
In which sector is GRI Bio located?▼
GRI Bio operates in the Health & Wellness sector.
When did GRI Bio complete a stock split?▼
The last stock split for GRI Bio was on January 26, 2026 with a ratio of 1:28.
Where is GRI Bio headquartered?▼
GRI Bio is headquartered in La Jolla, United States.